Keyphrases
Adipose-derived Stromal Cells
100%
Mesenchymal Stromal Cells
79%
Allogeneic
39%
Ischemic Heart Failure
28%
Mesenchymal Stem Cell Therapy
25%
Cell Treatment
23%
Human Mesenchymal Stem Cells (hMSCs)
23%
Randomized Placebo-controlled Trial
20%
Ischemic Heart Disease
19%
Cryopreserved
19%
Left Ventricular Ejection Fraction
18%
Intramyocardial Injection
17%
Placebo
17%
Adipose-derived Mesenchymal Stem Cells (ADMSCs)
15%
Vascular Endothelial Growth Factor
15%
Left Ventricular End-diastolic Volume (LVEDV)
15%
Clinical Application
15%
Culture Expansion
14%
Paracrine
14%
Human Platelet Lysate
14%
Angiogenesis
14%
Intramyocardial
13%
Adipokinetic Hormone
13%
Stem Cells
13%
Cellular Products
11%
Cardiology
11%
Rat Model
11%
Healthy Donors
11%
Heart Failure
11%
Head-and-neck Cancer
11%
Refractory Angina
11%
Mode of Action
10%
Heart Failure with Preserved Ejection Fraction (HFpEF)
10%
Chronic Ischemic Heart Disease
10%
Cryopreservation
10%
Stromal Cell Therapy
9%
Cancer Patients
9%
Fetal Bovine Serum
9%
NODAGA
9%
Serum Deprivation
9%
Potency Assay
9%
Radiation-induced Xerostomia
9%
Juxtacrine
9%
Alginate Hydrogel
9%
Dry Eye
9%
Allogeneic Mesenchymal Stem Cells
9%
Safety Study
9%
Immunomodulatory
9%
Cell Therapy
8%
Between-group
8%
Medicine and Dentistry
Adipose Tissue
74%
Stromal Cell
69%
Mesenchymal Stem Cell
58%
Placebo
41%
Heart Failure
39%
Heart Muscle Ischemia
31%
Ischemic Heart Disease
24%
Heart Left Ventricle Ejection Fraction
22%
Cell Therapy
21%
Stem Cell
14%
Xerostomia
13%
End-Systolic Volume
12%
Angina pectoris
11%
Cardiology
11%
Adipose-Derived Mesenchymal Stem Cell
10%
Head and Neck Cancer
10%
Mesenchymal Stem Cell Transplantation
10%
Positron Emission Tomography
9%
Copper 64
9%
Platelet Lysate
9%
Dry Eye
9%
Eye Disease
9%
Adverse Event
9%
New York Heart Association Class
8%
Bone Marrow Stromal Cell
8%
In Vitro
8%
Stem Cell Therapy
7%
Vasculotropin
7%
Magnetic Resonance Imaging
7%
Quality of Life
6%
Heart Function
6%
Symptom
6%
Cell Expansion
5%
Iron Oxide
5%
Ultrasmall Superparamagnetic Iron Oxide
5%
Phase II Trials
5%
Lacrimal Gland
5%
Hyposalivation
5%
Myocardium
5%
